Kopran: Uncertain Future - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Kopran: Uncertain Future

Sep 6, 2001

Kopran, promoted by Parijat Enterprise, is one of the integrated domestic pharmaceutical players. Its products Aten (cardiovascular), Vent (respiratory) and Smyle enjoy strong brand equity. The company is in the midst of business and financial restructuring. The company is trying to change the perception and business profile from that of a commodity bulk manufacturer and supplier to a formulations based company with an ability to create strong brands. In the first phase of restructuring process the company hived off of its penicillin based bulk business into a separate company (KDL Biotech). In the second phase, the OTC business of privately owned Kopran Pharmaceuticals Ltd. was merged with Kopran Ltd. The company intends to focus on the OTC segment and so far the company's brand 'Smyle' has created strong brand equity.

As per recent reports, Kopran is in talks with several pharmaceutical companies for sale of its formulations business or its 'Aten' brand in the cardiovascular segment. This comes as a surprise as bulk of company’s revenues in the formulations business come from the ‘Aten' brand. This could be due to the fact that the financial situation of the company is precarious with high debt levels. The debt/equity ratio is already alarming at 1.2:1. The financial performance of the company is also fluctuating.

Kopran-Rising Interest Burden
Quarter Ended 30/9/0031/12/0031/3/0130/6/01
Sales (Rs. Mn.)529568607478
Operating Margin (%)20%20%12%25%
Interest Burden (Rs.Mn.)51528078
PBT (%)9%8%4%4%

At the current market price of Rs 40 the stock is trading at 7x its 1QFY02 earnings. In wake of the recent development regarding the proposed sale of its formulation business, the future business plan of the company remains uncertain. It is likely that the company would concentrate purely on the OTC segment where it will have to work hard to establish strong brands.


Equitymaster requests your view! Post a comment on "Kopran: Uncertain Future". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why am I Recommending Caution? (Fast Profits Daily)

Sep 9, 2020

This is why I have changed my short-term view on the market.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS